Clinical insights into Epidyolex – a cannabis-based antiseizure medication [Podcast]

15 Sep 2022

Epidyolex (cannabidiol) is the first cannabis-based antiseizure medication approved for add-on therapy in patients with Dravet syndrome and Lennox-Gastaut syndrome. It is reimbursed on the PBS as add-on treatment in Dravet syndrome.

These podcasts feature Doctor Kaitlyn Parratt in conversation with Professor Emilio Perucca as they explore the pharmacology, study data, and clinical use of Epidyolex as an antiseizure medication.


Ep 1: Dr Parratt asks Prof. Perucca for his thoughts on whether the improved seizure control with Epidyolex seen in clinical trials is related to a direct action of cannabidiol or mediated by drug interactions with concomitant medications.


Ep 2:  Prof. Perucca and Dr Parratt discuss the pharmacology and clinical use of Epidyolex in Dravet syndrome.

Professor Emilio Perucca is an international expert in the clinical pharmacology of epilepsy. Before moving to Australia at the end of 2021, he was Professor at the University of Pavia and Director of the Clinical Trial Centre of the C. Mondino National Neurological Institute in Pavia. He trained as a neurologist and clinical pharmacologist at the National Hospital for Nervous Diseases, London. He has published a number of papers on the pharmacology of Epidyolex. 

Kaitlyn Parratt is Vice-President of the Epilepsy Society of Australia and Staff Specialist Neurologist and Epileptologist at the Comprehensive Epilepsy Service, Royal Prince Alfred Hospital in Sydney.




This podcast was sponsored by Chiesi Australia. Any views expressed are those of the experts alone and do not necessarily reflect the views of the sponsor. Before prescribing, please review the Epidyolex product information via the TGA website. Treatment decisions based on information in this podcast are the responsibility of the prescribing physician.

Already a member?

Login to keep reading.

Email me a login link